All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-13T14:53:49.000Z

Management of complications of CAR T-cell therapies in Europe

Sep 13, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute lymphoblastic leukemia.

A survey conducted by the European Society for Blood and Marrow Transplantation (EBMT) assessed the management of short- and long-term complications in patients with acute lymphoblastic leukemia, lymphoma, and multiple myeloma who were treated with chimeric antigen receptor (CAR) T-cell therapies. The survey included 106 EBMT CAR T-cell centers and was carried out between February 23, 2023, and April 27, 2023. Results from this survey were published in Haematologica by Penack et al.1

Key learnings

The management of steroid-refractory and very severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were identified as critical areas needing harmonization in treatment approaches. Anakinra was widely used in severe cases, but optimal dosing remains undetermined, indicating a need for further research.

Prolonged cytopenias post CAR T-cell therapy were common, yet there is no consensus on the best management strategy. While more than half of centers considered stem cell boosts, the timing and criteria for this intervention vary widely, underscoring the need for more robust evidence-based protocols.

Immunoglobulin G deficiency management post CAR T-cell therapy was inconsistent, with practices ranging from routine substitution in asymptomatic patients to only treating severe cases. This variation suggests a need for more definitive guidelines to optimize patient outcomes.

The management of CAR T-cell therapy complications showed significant variability across European centers, highlighting a need for standardized treatment guidelines. This inconsistency in practice reflects a reliance on expert knowledge due to the lack of extensive clinical trial data. These results suggest a need for the collection of more clinical evidence, by integrating concepts for complication management in clinical trials, and increasing collaborative efforts of harmonization.

  1. Penack O, Peczynski C, Boreland W, et al. Management of complications of chimeric antigen receptor T-cell therapy: A report by the European Society of Blood and Marrow Transplantation. 2024. Online ahead of print. DOI: 10.3324/haematol.2023.284810

Your opinion matters

I commit to reviewing the latest clinical data and recommendations for the optimal dosing of recombinant asparaginase in ALL to reduce and manage toxicities.
1 vote - 87 days left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox